4564564564

Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention [defined as per U.S Department of Health & Human Services]. They are the primary way that researchers find out if a new treatment, like a form of drug, or a medical device is safe and effective for the people. Often a clinical trial is used to learn if a new treatment is more effective and/or has less harmful side effects than the standard treatment.

Lagging behind the rest.

While a few years ago, India conducted 1.5 per cent of global clinical trials and studies, as per the International Repository of Clinical Trials data, this has now fallen to 1.2 per cent. The data further reported that out of 2,97,101 clinical trials [as on February 13th, 2019], a mere 3,618 trials(~1.2 %) are occurring in India. As per the World Health Organization, India’s population is 1.32 billion (i.e. ~17 % of global population), shares 20 per cent of the global disease burden and yet only 1.2 per cent of global clinical trials are done in India. This is a huge worrying sign for the Government of the day.

What are the new rules?

To abridge these gaps, recently, the new set of clinical trials rules have been proposed, which are likely to be notified in March. The rules will enable fast-track proposal clearances for Indian companies rather than their multi-national counterparts. Indian companies will be provided incentive to start clinical trials and their proposals will be deemed approved in case they do not hear from the Director Controller General of India (DCGI) on the status of their application within 30 days. What this entails is that while the domestic approvals will be fast-tracked, for the multinational companies, on the other hand, the waiting period will be defined mostly at six months in the notified rules. These rules are framed in the hope that the indigenous pharmaceutical companies will jump-start the dormant drug research efforts in the country.

Prior to these, pharmaceutical companies, be it domestic or multinational companies, had no clue as to when their paperwork would be accepted by the office of DCGI. This resulted in confusion, delayed conduction of clinical trials and eventual decrease in general levels of drug research in the pharmaceutical companies as there was no leverage to perform the same. The famed generic pharmaceutical companies had no impetus to carry out research on its own. These new rules would boost the indigenous pharmaceutical research in the country and would help bring more global trials both from domestic and multinational companies.

Compensation clause.

In the new rules, the DCGI has, further, decided to change the compensation clause in case of death or disability presumably caused by the clinical trials. Earlier, the rules had said 60 per cent of the amount would be non-refundable, even if an expert committee at a later stage found the death or the disability was not related to the clinical trial. Now the clause of amount being non-refundable has been done away with.

The current rules which were notified in 2015, provide for compensation to those enrolled in clinical trials according to a set formula, when the applicants were compensated anywhere from Rs. 4 lakhs to Rs. 75 lakhs, and that clause will be continued in the new rules as well. It is worth mentioning that, since 2015, according to Ministry of Health and Family Welfare in pursuance to a report tabled in Parliament, close to Rs. 5 crore has been paid in compensation to those enrolled in clinical trials.

Thus, the new proposed clinical trials rules, ensures that India is treading a path to achieve the Sustainable Development Goal 3, erected by the UN, by giving impetus to the indigenous pharmaceutical companies to carry out drug research. This ensures cheap and effective drugs for ailments where there wasn’t any alternative remedy except the expensive drugs manufactured by multinational companies. This will further boost the medical research eco-system prevailing in the country.

Jashan Preet Singh Sidhu

Associate Partner, Aggarwals & Associates, Mohali.

 

Disclaimer & Confirmation

It is herein expressly intimated to you that the current rules of the Bar Council of India do not permit lawyers to solicit work or advertise their services. Please note that this website (hereinafter referred to as the “Website”) is a public resource website and provides general information about the location of the firm “Aggarwals & Associates”. Further, note that –

    • This Website is a resource website for non-commercial general information and educational purposes only.
    • There has been no advertisement, personal communication, solicitation, invitation or inducement of any kind whatsoever from Aggarwals & Associates, or any of its members, to solicit any work or create an Attorney-Client relationship through its Website.
    • Aggarwals & Associates does not guarantee or undertakes any warranties concerning the accuracy or completeness of the information provided on the Website.
    • Nothing on this Website should be interpreted to constitute any legal advice.
    • Aggarwals & Associates is not liable for any consequences arising out of any action taken by the visitor / user relying on the material/information provided on this website, and the visitor / user should seek the advice of competent counsel licensed to practice in the relevant country/state for any legal issue.

By proceeding further and clicking on “I Agree” button herein below, the visitor/user acknowledges that he/she on his own accord wishes to know more about Aggarwals & Associates and browse the website for his/her own information and use. The visitor/user further acknowledges that there has been no solicitation, invitation or inducement of any kind whatsoever from Aggarwals & Associates or from any of its members to create an Attorney-Client relationship through this website. The visitor/user further acknowledges having gone through and understood the contents of this Disclaimer.

Call Now
Directions